1187928-85-3

Basic information

• Product Name: 4-(4-Bromo-phenyl)-1-methyl-piperidine
• Synonyms: 4-(4-Bromo-phenyl)-1-methyl-piperidine
• CAS NO: 1187928-85-3
• Molecular Weight: 254.17
• Mol File: 1187928-85-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(4-Bromo-phenyl)-1-methyl-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Bromo-phenyl)-1-methyl-piperidine(1187928-85-3)
• EPA Substance Registry System: 4-(4-Bromo-phenyl)-1-methyl-piperidine(1187928-85-3)

Safety Data

• Hazardous Substances Data: 1187928-85-3(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 769944-79-8 4-(4-bromophenyl)piperidine hydrogen chloride salt 
• 80980-89-8 4-(4’-bromophenyl)piperidine 

Downstream Products

• 1247000-92-5 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine 
• 1467059-12-6 6-chloro-5-(4-(1-methylpiperidin-4-yl)phenyl)-1H-indazole-3-carboxylic acid 

Relevant articles and documents

SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN

The present invention relates to compounds of formula (I) and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

HETEROARYL SYK INHIBITORS

The invention relates to new substituted heteroarylsof formula (1) wherein A is selected from the group consisting of N and CH, D is selected from the group consisting of S and O, E is C, T is C, G is C, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.